OCM
BTAI icon

Oaktree Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Oaktree Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$323K Hold
241,188
– – ﹤0.01% 146
2025
Q4 		$386K Hold
241,188
– – 0.01% 171
2025
Q3 		$617K Hold
241,188
– – 0.01% 164
2025
Q2 		$437K Buy
+241,188
New +$399K 0.01% 177

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Oaktree Capital Management's BTAI Position: Q1 2026 in Review

Oaktree Capital Management held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 241,188 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #146.

Oaktree Capital Management first reported a position in BTAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $617K in Q3 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Oaktree Capital Management held 241,188 shares of BioXcel Therapeutics worth $323K as of Q1 2026.
  • Oaktree Capital Management left its BioXcel Therapeutics share count unchanged in Q1 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Oaktree Capital Management's portfolio in Q1 2026, its #146 holding.
  • Oaktree Capital Management first reported a position in BioXcel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Oaktree Capital Management's BioXcel Therapeutics position peaked at $617K in Q3 2025.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Oaktree Capital Management's 13F filing for Q1 2026, filed 15 May 2026.